Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
16.96 USD | -0.85% | -1.19% | -47.17% |
04-23 | Neuren Pharmaceuticals' Medication Secures Priority Review from Health Canada | MT |
04-22 | Acadia Pharmaceuticals' Rett Syndrome Treatment Granted Priority Review by Health Canada | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-47.17% | 2.82B | |
+0.98% | 42.86B | |
+10.97% | 42.74B | |
+44.59% | 41.36B | |
-8.83% | 27.68B | |
+7.52% | 25.15B | |
-23.93% | 18.63B | |
+30.66% | 12.37B | |
-2.15% | 11.92B | |
+6.85% | 11.21B |
- Stock Market
- Equities
- ACAD Stock
- News ACADIA Pharmaceuticals Inc.
- Sector Update: Health Care Stocks Adding to Midday Gains Near Close